ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2018
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Hepatitis-B virus reactivation during Immunosuppressive therapy: Clinical observations from a tertiary care center.Pakistan journal of medical sciences · 2026Article
- Increased Risk of Hepatitis B Virus Reactivation in Patients with Resolved Hepatitis B Virus Infection Receiving Combination Immunosuppressive Therapy: The Role of Anti-HBs Status.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review.Journal of translational medicine · 2026Review
- Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy.Hepatology forum · 2026Article
- Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.Acta neurologica Belgica · 2024Review
- Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.Journal of neurology · 2024Observational
- Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- [Viral Hepatitis in Patients with Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Review
- [Drugs and hepatitis B virus reactivation].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2022Article
- Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review).Experimental and therapeutic medicine · 2022Review
- Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.World journal of gastroenterology · 2021Review
- Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic LeukemiaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Article
- Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Is there any evidence implying the use of a different criterion for protective anti-HBs titer after HBV vaccination in immunosuppressed patients?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Moderate Risk of Hepatitis B Virus Reactivation in HBsAgScientific reports · 2020Article
- Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report.World journal of clinical cases · 2019Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.